IL-33 induces innate lymphoid cell–mediated airway inflammation by activating mammalian target of rapamycin

Salmond, R.J., Mirchandani, A.S., Besnard, A.-G., Bain, C.C., Thomson, N.C. and Liew, F.Y. (2012) IL-33 induces innate lymphoid cell–mediated airway inflammation by activating mammalian target of rapamycin. Journal of Allergy and Clinical Immunology, 130(5), pp. 1159-1166. (doi: 10.1016/j.jaci.2012.05.018)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1016/j.jaci.2012.05.018

Abstract

<b>Background:</b> The IL-1 family cytokine IL-33 is involved in the induction of airway inflammation in allergic patients and after viral infection. Several cell types, including CD4+ TH2 cells and the recently described type 2 innate lymphoid cells (ILCs), are targets for IL-33, yet the mechanisms by which this cytokine modulates their activation are not clear.<p></p> <b>Objectives:</b> Our goal was to investigate a role for mammalian target of rapamycin (mTOR) signaling in the activation of TH2 and ILC responses and the induction of airway inflammation by IL-33.<p></p> <b>Methods:</b> We biochemically determined the effect of IL-33 on mTOR activation in TH2 cells and ILCs and examined the effect of this signaling pathway in vivo using a murine model of IL-33–induced lung inflammation.<p></p> <b>Results:</b> We found that IL-33 induces mTOR activation through p110δ phosphoinositide 3-kinase and that blockade of the mTOR pathway inhibited IL-33–induced IL-5 and IL-13 production by TH2 cells and ILCs. Furthermore, use of a ribosomal protein S6 kinase 1 inhibitor implicated a role for ribosomal protein S6 kinase 1 in IL-33–induced mTOR-dependent cytokine production. Intranasal administration of IL-33 to wild-type mice induced airway inflammation, whereas adoptive transfer of wild-type ILCs to IL-33 receptor–deficient (St2−/−) mice recapitulated this response. Importantly, coadministration of the mTOR inhibitor rapamycin reduced IL-33–dependent ILC, macrophage, and eosinophil accumulation; cytokine secretion; and mucus deposition in the airways.<p></p> <b>Conclusion:</b> These data reveal a hitherto unrecognized role of mTOR signaling in IL-33–driven, ILC-dependent inflammation in vivo and suggest that manipulation of this pathway might represent a target for therapeutic intervention for airway inflammation.<p></p>

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Liew, Prof Foo and Bain, Mr Calum and Mirchandani, Dr Ananda and Besnard, Dr Anne-Gaelle and Thomson, Professor Neil and Salmond, Dr Robert
Authors: Salmond, R.J., Mirchandani, A.S., Besnard, A.-G., Bain, C.C., Thomson, N.C., and Liew, F.Y.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Journal of Allergy and Clinical Immunology
Journal Abbr.:J. Allergy Clin. Immunol.
Publisher:Mosby, Inc.
ISSN:0091-6749
ISSN (Online):1097-6825
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
486461The role of IL-35 in infection and inflammationFoo LiewMedical Research Council (MRC)G0801198III -IMMUNOLOGY
522591The role of nitric oxide-induced regulatory T cells in inflammationFoo LiewMedical Research Council (MRC)G0902003III -IMMUNOLOGY